Anti-viral guanosine-rich oligonucleotides
AssigneeAronex Pharmaceuticals, Inc.
InventorsRobert F. Rando, Susan Fennewald, Joseph G. Zendegui, Joshua O. Ojwang, Michael E. Hogan
Life of this patent
Estimating the term…
Abstract
A method and compositions for treating viral infection in vitro and in vivo using a guanosine-rich oligonucleotides. The oligonucleotides have sufficient guanosine to form a guanosine tetrad. They can be composed of at least about 40% guanosine nucleotides. Also provided are oligonucleotides of at least two runs of at least two guanosines. Also provided are guanosine-rich oligonucleotides and methods for treating viral infections in humans, and a method for designing guanosine-rich oligonucleotides having anti-viral activity.
Claims1
A method of inhibiting the production of HIV-1 in cultured cells comprising contacting said virus with an oligonucleotide having a sequence chosen from the group consisting of
- 5'-gtggtgggtgggtgggg-3' (SEQ ID NO 46)
- 5'-gtggtgggtgggtggg-3' (SEQ ID NO 47)
- 5'-tggtgggtgggtgggt-3' (SEQ ID NO 48)
- 5'-gtggtgggtgggt-3' (SEQ ID NO 49)
- 5'-gtggtgggt-3' (SEQ ID NO 50)
- 5'-gtgggtgggtgggt-3' (SEQ ID NO 51)
- 5'-gtgggtgggt-3' (SEQ ID NO 52),
- optionally modified at the 3' terminus by attachment of a substituent moiety selected from the group consisting of propylamine, polyamine, poly-L-lysine, and cholesterol,
- optionally modified at the 5' terminus by attachment of a substituent moiety selected from the group consisting of propylamine, polyamine, poly-L-lysine, and cholesterol, and
- optionally modified by replacement of at least one phosphodiester moiety with a phosphorothioate moiety.
Dependencies are inferred from the claim text.